Verdonck, Michaƫl http://orcid.org/0000-0002-1927-3151
Carvalho, Hugo http://orcid.org/0000-0002-5784-5480
Fuchs-Buder, Thomas
Brull, Sorin J. http://orcid.org/0000-0003-2607-2590
Poelaert, Jan http://orcid.org/0000-0002-0065-2899
Funding for this research was provided by:
Agentschap Innoveren en Ondernemen (Innovation mandate, Innovation mandate, Innovation mandate)
Vrije Universiteit Brussel (Industrial Research Fund, Industrial Research Fund, Industrial Research Fund)
Wetenschappelijk Fonds Willy Gepts (Unrestricted research grant, Unrestricted research grant)
Society for Anaesthesia and Resuscitation of Belgium (Unrestricted research grant, Unrestricted research grant)
Article History
Received: 17 October 2023
Accepted: 9 February 2024
First Online: 4 April 2024
Declarations
:
: HC has received lecture fees from 3M (Diegem, Belgium) and Xavant Technology (Pretoria, South Africa); SJB has intellectual property assigned to Mayo Clinic (Rochester, MN); has received research support (funds to Mayo Clinic) from Merck & Co, Inc (Kenilworth, NJ) and is a consultant for Merck & Co, Inc; is a principal, shareholder, and chief medical officer in Senzime AB (publ) (Uppsala, Sweden); and is a member of the scientific/clinical advisory boards for the Doctors Company (Napa, CA), Coala Life, Inc (Irvine, CA), NMD Pharma (Aarhus, Denmark), and Takeda Pharmaceuticals (Cambridge, MA); TFB received lecture fees from MSD France. MV and JP declare no competing interests.